Published in Biotech Law Weekly, April 8th, 2005
According to recent research from the United States, "Geldanamycin (GA) is a potent anticancer antibiotic that inhibits Hsp-90. Its potential clinical utility is hampered by its severe toxicity. To alleviate this problem, we synthesized a series of carbohydrate-geldanamycin conjugates for enzyine-specific activation to increase tumor selectivity."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.